Studies why myeloma stops responding to treatment over time
Follows adults with multiple myeloma to learn how it resists treatment.
Plain-language title generated from the registry record
Registry title: MYeloma Resistance And Clonal Evolution
Key facts
- Where
- La Roche-sur-Yon and Nantes, FranceSee the 2 sites
Where in France
- La Roche sur Yon Hospital DepartmentalLa Roche-sur-Yon, FranceTaking people
- Nantes University HospitalNantes, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nantes University Hospital
- Trial code
- NCT03807128
- Record updated
- 14 July 2025
- Original description
Multiple Myeloma (MM) is often associated with progression, temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis. Because MM is classified as an incurable disease, therapeutic resistance is of great interest. However, knowledge about the biological mechanisms underlying resistance associated with MM therapies and about associated predictors remains poor. The MYRACLE cohort, a multicenter prospective cohort of patients with MM, is set up to address this limitation.Read full original descriptionShow less
MYeloma Resistance And Clonal Evolution
Multiple Myeloma (MM) is often associated with progression, temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis. Because MM is classified as an incurable disease, therapeutic resistance is of great interest. However, knowledge about the biological mechanisms underlying resistance associated with MM therapies and about associated predictors remains poor. The MYRACLE cohort, a multicenter prospective cohort of patients with MM, is set up to address this limitation.
Inclusion: Patient consulting due to the discovery or recurrence of MM according to international diagnostic criteria (IMWG 2014); Patient having consented to participate in the study and his/her biocollection; Patient affiliated to or benefiting from a social security scheme or similar.
Exclusion: Minors; Major under guardianship or curatorship; Protected persons; Pregnant or breast-feeding women; Persons benefiting from the AME.